Aflibercept

Uncategorized

Aflibercept

What is Aflibercept
?

Aflibercept is a recombinant fusion protein consisting of the extracellular ligand-binding domain of vascular endothelial growth factor receptor-1 (VEGFR-1) and the Fc domain of human IgG1. Aflibercept binds to VEGF-A, VEGF-B, and VEGF-C with high affinity and blocks their binding to VEGFR-1, VEGFR-2, and VEGFR-3.

Aflibercept is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME).

Aflibercept is also indicated for the treatment of patients with cancer (non-small cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme) in combination with chemotherapy

Benefits of Aflibercept
and Its Uses.

Aflibercept is a recombinant fusion protein consisting of the extracellular domains of vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2) linked to the Fc domain of human IgG1. Aflibercept binds to VEGF-A, VEGF-B, and VEGF-C, inhibiting the binding of VEGF to its receptor, VEGFR-1, VEGFR-2, and VEGFR-3.

Aflibercept is used to treat wet age-related macular degeneration (AMD), a condition in which the central part of the retina (the macula) slowly loses its ability to see fine details. Aflibercept is also used to treat cancer that has spread to the eye (metastatic retinoblastoma).

Aflibercept is in a class of medications called VEGF inhibitors. It works by blocking

Side Effects and Dosage of Aflibercept

Aflibercept is a recombinant fusion protein consisting of the extracellular ligand-binding domain of vascular endothelial growth factor A (VEGF-A) fused to the Fc portion of human IgG1. Aflibercept binds to all VEGF receptors, which leads to inhibition of angiogenesis and tumor growth.

Aflibercept is used to treat age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It is also being studied for other conditions, such as cancer.

Aflibercept is administered by injection into the eye.

The recommended dosage of aflibercept depends on the condition being treated.

For wet AMD, the recommended starting dosage is 2 mg administered by injection into the eye every 2 weeks.

For DME, the recommended starting dosage is 2 mg administered by injection into the eye every 4

Category: Uncategorized
Posts created 12429

Leave a Reply

Your email address will not be published.

Related Posts

Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top